Form 8-K - Current report:
SEC Accession No. 0001493152-24-045283
Filing Date
2024-11-14
Accepted
2024-11-14 06:16:03
Documents
18
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48221
2 ex99-1.htm EX-99.1 253808
3 ex99-2.htm EX-99.2 187689
4 ex99-1_001.jpg GRAPHIC 16374
5 ex99-2_001.jpg GRAPHIC 19381
  Complete submission text file 0001493152-24-045283.txt   814531

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE hrow-20241113.xsd EX-101.SCH 3944
7 XBRL DEFINITION FILE hrow-20241113_def.xml EX-101.DEF 30369
8 XBRL LABEL FILE hrow-20241113_lab.xml EX-101.LAB 37183
9 XBRL PRESENTATION FILE hrow-20241113_pre.xml EX-101.PRE 27388
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6655
Mailing Address 102 WOODMONT BLVD SUITE 610 NASHVILLE TN 37215
Business Address 102 WOODMONT BLVD SUITE 610 NASHVILLE TN 37215 615.733.4731
HARROW, INC. (Filer) CIK: 0001360214 (see all company filings)

EIN.: 450567010 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35814 | Film No.: 241456875
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)